TGF-β attenuates aGVHD after allogeneic SCT
. | G-CSF allogeneic anti-TGF-β . | G-CSF allogeneic control antibody . | G-CSF syngeneic anti-TGF-β . |
|---|---|---|---|
| Day 35 survival, % | 17* | 83 | 100 |
| Clinical score, mean ± SE | |||
| Day 7 | 4.6 ± 0.1* | 3.3 ± 0.2 | 1.8 ± 0.6 |
| Day 14 | 5.0 ± 0.4* | 2.8 ± 0.3 | 0 ± 0 |
| Day 21 | 5.3 ± 0.9† | 3.2 ± 0.2 | 0 ± 0 |
. | G-CSF allogeneic anti-TGF-β . | G-CSF allogeneic control antibody . | G-CSF syngeneic anti-TGF-β . |
|---|---|---|---|
| Day 35 survival, % | 17* | 83 | 100 |
| Clinical score, mean ± SE | |||
| Day 7 | 4.6 ± 0.1* | 3.3 ± 0.2 | 1.8 ± 0.6 |
| Day 14 | 5.0 ± 0.4* | 2.8 ± 0.3 | 0 ± 0 |
| Day 21 | 5.3 ± 0.9† | 3.2 ± 0.2 | 0 ± 0 |
Lethally irradiated B6D2F1 recipients underwent transplantation with splenocytes from G-CSF-treated allogeneic B6 (n = 6 per group) or syngeneic B6D2F1 (n = 4) donors, as described in “Materials and methods.” Recipients received anti-TGF-β or control antibody (100 μg/dose intraperitoneally) at day 0 and then 3 times weekly until day 35. Transplant recipients were monitored for survival and clinical score, as described in “Materials and methods.”
*P < 0.1 and †P < .05 compared with G-CSF control antibody and syngeneic groups. Results represent 1 of 3 similar experiments.